Lepu Medical Technology (Beijing) has released its first-quarter 2024 financial results, showing a revenue decrease of 13% from the same period in 2023. Net income also fell by 19%, while the profit margin remained constant at 25%. Earnings per share (EPS) decreased to CN¥0.26 from CN¥0.32 in the first quarter of 2023.
Despite this, analysts had predicted higher revenue and EPS growth for Lepu Medical Technology (Beijing), with a forecasted growth rate of 19% compared to an industry average of 19%. However, the company’s shares have decreased by only 1.0% over the past week. It is important for investors to consider potential risks associated with investing in this company and seek out additional information, including fair value estimates, insider transactions, dividends, and financial health assessments before making any investment decisions.
